Latest News for: cel
Edit
Enid News & Eagle
23 Feb 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
Enid News & Eagle
23 Feb 2026
Edit
GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CEL (Form 8-K) (Gilead Sciences Inc)
Public Technologies 23 Feb 2026
GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CEL. - Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma -.
Edit
GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CEL (Form 8-K) (Arcellx Inc)
Public Technologies 23 Feb 2026
GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CEL. - Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative ... - FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with.
Edit
Lancaster Online
22 Feb 2026
Don and Grace Benkendorf Cel
Lancaster Online
22 Feb 2026
Don and Grace Benkendorf of Quarryville celebrate their 75th wedding anniversary on February 22. They were married in 1951 in New Jersey, beginning a life together marked by faith, devotion, and love. Don spent most of his career as a ... .
Edit
Quarterly Report for Quarter Ending December 31, 2025 (Form 10-Q) (CEL-SCI Corporation)
Public Technologies 17 Feb 2026
CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system.
Edit
Translational data for vispa-cel ANTLER Phase 1 clinical trial, Tandem Meetings 2026 poster (Caribou Biosciences Inc)
Public Technologies 06 Feb 2026
) Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL) ... Vispa-cel ... Readily available, single-dose administration with vispa-cel ... Vispa-cel ... Vispa-cel.
Edit
Trump facing cultural revolt against immigration crackdown
The Day 29 Jan 2026
NEW YORK (AP) — No longer confined to the partisans and activists, the fierce backlash against Donald Trump's immigration crackdown has begun to break out across American culture, spanning the worlds of business, sports and entertainment ... ....
Edit
Statement of Changes in Beneficial Ownership (Form 4) (CEL-SCI Corporation)
Public Technologies 26 Jan 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue ... CEL SCI CORP [CVM] 5 ... CEL-SCI Corporation published this content on January 26, 2026, and is solely responsible for the information contained herein.
Edit
‘I’m not sure I’d throw that responsibility on him’ – Martin O’Neill warns Tomas Cvancara is not answer to Cel
Irish Independent 21 Jan 2026
Edit
PR No. 175 FEDERAL MINISTER FOR SCIENCE & TECHNOLOGY ADDRESSES 25TH ANNIVERSARY CEL (Ministry of Information and Broadcasting of the Islamic Republic of Pakistan)
Public Technologies 21 Jan 2026
Addressing the ceremony attended by Federal Secretary, Ministry of Science & Technology, Shahid Iqbal Baloch, Rector COMSATS University Islamabad Professor Dr ... He appreciated the leadership of Professor Dr ... Attachments Original document Permalink.
Edit
Polk County Itemiser-Observer
13 Jan 2026
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
Polk County Itemiser-Observer
13 Jan 2026
SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan.
Edit
The Joplin Globe
12 Jan 2026
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
The Joplin Globe
12 Jan 2026
Edit
Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
Business Wire 12 Jan 2026
The trial will evaluate DISP-11, an investigational therapy leveraging Disp .
- 1
- 2
- Next page »